Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details)

Subsequent Events (Details) $ / shares in Units, $ in Thousands						1 Months Ended					6 Months Ended
	Jul. 25, 2024 USD ($) $ / shares shares	Jul. 15, 2024 USD ($) director D	Jul. 05, 2024 USD ($) $ / shares	Dec. 27, 2023 USD ($)	Dec. 30, 2022 USD ($) $ / shares shares	Jul. 31, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	May 31, 2024 USD ($) $ / shares shares	Apr. 30, 2024 USD ($) $ / shares shares	Jan. 31, 2024 USD ($) $ / shares shares	Jun. 30, 2024 USD ($) $ / shares shares	Jun. 30, 2023 USD ($)	Jul. 09, 2024 USD ($)	Jun. 27, 2024 $ / shares	Jan. 09, 2024 $ / shares	Dec. 31, 2023 USD ($) $ / shares	Oct. 11, 2022 $ / shares	Aug. 31, 2020 USD ($)	Aug. 27, 2020 USD ($)
Subsequent Events
Stock offering, number of shares issued \| shares					4,900,000
Sale of National Holding's stock, proceeds received					$ 150,000
Common Stock, par value \| $ / shares					$ 0.0001		$ 0.001				$ 0.001					$ 0.001
Proceeds from Warrant Exercises											$ 30	$ 0
Avenue
Subsequent Events
Number of warrants to purchase shares \| shares									689,680
Exercise price of warrants \| $ / shares									$ 6.20								$ 116.25
Avenue \| Minimum
Subsequent Events
Warrant expiration term									18 months
Avenue \| Maximum
Subsequent Events
Warrant expiration term									5 years
Avenue \| Series A Warrants
Subsequent Events
Stock offering, price per share \| $ / shares															$ 22.545
Avenue \| Series B Warrants
Subsequent Events
Stock offering, price per share \| $ / shares															$ 22.545
Avenue \| Unregistered warrants
Subsequent Events
Number of warrants to purchase shares \| shares									1,379,360
Exercise price of warrants \| $ / shares									$ 6.20
Stock offering, price per share \| $ / shares									$ 0.125
Total gross proceeds								$ 3,900	$ 3,700
Urica \| Common Stock Warrant
Subsequent Events
Exercise price of warrants \| $ / shares														$ 1.68
Warrant expiration term														5 years
Direct offering
Subsequent Events
Exercise price of warrants \| $ / shares										$ 3.21
Stock offering, number of shares issued \| shares										3,303,305
Warrant expiration term										5 years
Sale of National Holding's stock, proceeds received										$ 10,200
Unit Price Per Share \| $ / shares										$ 3.33
Direct offering \| Maximum
Subsequent Events
Number of warrants to purchase shares \| shares										3,303,305
Direct offering \| Checkpoint Common Stock Warrants
Subsequent Events
Stock offering, price per share \| $ / shares										$ 1.805
Sale of National Holding's stock, proceeds received										$ 12,600
Direct offering \| Checkpoint Common Stock Warrants \| Maximum
Subsequent Events
Number of warrants to purchase shares \| shares										7,756,233
Direct offering \| Checkpoint Common Stock Warrants \| Common Stock Warrant
Subsequent Events
Exercise price of warrants \| $ / shares										$ 1.68
Warrant expiration term										5 years
Direct offering \| Checkpoint Common Stock Warrants \| Pre funded warrants
Subsequent Events
Exercise price of warrants \| $ / shares										$ 0.0001
Warrants issued \| shares										6,481,233
Number of shares called by warrants \| shares										1
Stock offering, price per share \| $ / shares										$ 1.8049
Direct offering \| Checkpoint Common Stock Warrants \| Placement Agent Warrants
Subsequent Events
Exercise price of warrants \| $ / shares										$ 2.2563
Direct offering \| Checkpoint Common Stock Warrants \| Placement Agent Warrants \| Maximum
Subsequent Events
Number of warrants to purchase shares \| shares										465,374
Direct offering \| Mustang
Subsequent Events
Number of warrants to purchase shares \| shares							3,105,000				3,105,000
Exercise price of warrants \| $ / shares							$ 0.001				$ 0.001
Stock offering, number of shares issued \| shares							3,025,000				575,191
Stock offering, price per share \| $ / shares							$ 0.4099				$ 0.4099
Warrant expiration term							5 years				5 years
Sale of National Holding's stock, proceeds received							$ 2,200
Direct offering \| Mustang \| Unregistered warrants
Subsequent Events
Number of warrants to purchase shares \| shares							6,130,000				6,130,000
Exercise price of warrants \| $ / shares							$ 0.41				$ 0.41
Public Offering \| Mustang
Subsequent Events
Number of warrants to purchase shares \| shares								50,632,914
Exercise price of warrants \| $ / shares								$ 0.237
Stock offering, number of shares issued \| shares								1,160,000
Stock offering, price per share \| $ / shares								$ 0.237
Proceeds from Warrant Exercises								$ 3,300
Public Offering \| Mustang \| Common Stock
Subsequent Events
Stock offering, number of shares issued \| shares								16,877,638
Public Offering \| Mustang \| Series A One Warrants
Subsequent Events
Warrant expiration term								5 years
Public Offering \| Mustang \| Series A Two Warrants
Subsequent Events
Warrant expiration term								24 months
Public Offering \| Mustang \| Series A Three Warrants
Subsequent Events
Warrant expiration term								9 months
Public Offering \| Mustang \| Amended Warrants
Subsequent Events
Number of warrants to purchase shares \| shares								2,588,236
Exercise price of warrants \| $ / shares								$ 0.237
Stock offering, price per share \| $ / shares								$ 1.58
Warrant expiration term								5 years
SWK Term Loan
Subsequent Events
Maximum borrowing capacity				$ 20,000
Basis spread on variable rate				7.75%
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]				us-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember
Debt instrument, floor rate				5
Total notes payable, gross							$ 20,000				$ 20,000					$ 15,000
Oaktree Note
Subsequent Events
Debt instrument face amount																		$ 60,000
Total notes payable, gross							$ 50,000				$ 50,000					$ 50,000			$ 50,000
Subsequent Events
Subsequent Events
Debt Instrument, number of interest only period	30 months
Subsequent Events \| Scenario when the outstanding principal balance is less than or equal to 10 million
Subsequent Events
Minimum liquidity to be maintained	$ 0
Minimum net sales to be maintained	0
Subsequent Events \| Scenario when the outstanding principal balance is between 10 million and 25 million
Subsequent Events
Minimum liquidity to be maintained	5,000
Increase in minimum liquidity to be maintained under each instance of product disapproval as per the debt agreement	3,750
Subsequent Events \| 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock [Member]
Subsequent Events
Preferred Stock, Monthly Dividends, Per Share, Paused \| $ / shares			$ 0.1953125
Preferred Stock, dividend rate percentage			9.375%
Deferred Dividends			$ 700
Subsequent Events \| Crystalys Therapeutics, Inc [Member]
Subsequent Events
Capitalization in equity securities		$ 150,000
Subsequent Events \| Urica
Subsequent Events
Percentage of equity to be held		35.00%
Subsequent Events \| Urica \| Crystalys Therapeutics, Inc [Member]
Subsequent Events
Urica's equity position		15.00%
Percentage of royalty on future net sales		3.00%
Number of directors \| director		1
Number of days to provide transition support \| D		90
Subsequent Events \| July 2024 Registered Direct Offering [Member] \| Checkpoint Common Stock Warrants
Subsequent Events
Number of warrants to purchase shares \| shares						5,853,659
Exercise price of warrants \| $ / shares						$ 2.05
Stock offering, number of shares issued \| shares						1,230,000
Warrants issued \| shares						4,623,659
Stock offering, price per share \| $ / shares						$ 2.05
Total gross proceeds						$ 12,000
Warrant expiration term						5 years
Subsequent Events \| July 2024 Registered Direct Offering [Member] \| Checkpoint Common Stock Warrants \| Pre funded warrants
Subsequent Events
Exercise price of warrants \| $ / shares						$ 2.0499
Subsequent Events \| SWK Term Loan
Subsequent Events
Maximum borrowing capacity													$ 25,000
Line of credit facility additional borrowing capacity													$ 5,000
Subsequent Events \| Oaktree Note
Subsequent Events
Proceeds from debt	35,000
Debt instrument, unused borrowing capacity, amount	15,000
Debt instrument face amount	$ 50,000
Basis spread on variable rate	7.625%
Debt Instrument, Variable Interest Rate, Type [Extensible Enumeration]	us-gaap:SecuredOvernightFinancingRateSofrMember
Debt instrument, floor rate	2.50
Debt instrument, cap rate	5.75
Debt instrument, percentage of then outstanding principal balance due on a specified date	50.00%
Debt instrument, aggregate of principal prepayment amount, minimum	$ 5,000
Debt instrument, aggregate of principal prepayment amount in multiples	1,000
Excess proceeds from any of company's subsidiaries other than in connection with certain monetization events	5,000
Minimum liquidity to be maintained	7,000
Minimum net sales to be maintained	$ 50,000
Minimum net sale trailing period	12 months
Debt instrument, threshold amount of aggregate common equity or cash distributions to be received	$ 20,000
Percentage of amount set forth in annual budget	50.00%
Outstanding principal balance	$ 10,000
Number of warrants to purchase shares \| shares	506,390
Exercise price of warrants \| $ / shares	$ 2.0735
Total notes payable, gross	$ 50,000